登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《LANCET，4月1日，Excitement around hydroxychloroquine for treating COVID-19 causes challenges for rheumatology》

  • 来源专题：COVID-19科研动态监测
  • 编译者： xuwenwhlib
  • 发布时间：2020-04-02

  • Excitement around hydroxychloroquine for treating COVID-19 causes challenges for rheumatology

    Brian Owens

    Published:April 01, 2020DOI:https://doi.org/10.1016/S2665-9913(20)30089-8

    Excitement about a potential new treatment for the coronavirus disease 2019 (COVID-19) pandemic currently engulfing the world is causing problems for patients with arthritis and systemic lupus erythematosus (SLE), who routinely use the drug to control their symptoms.

    The antimalarial drug chloroquine and its safer derivative hydroxychloroquine have been used since the 1940s to treat autoimmune disorders, says Thomas Dörner, a rheumatologist at the Charité University Hospital in Berlin. Though the drug is rarely used for rheumatoid arthritis, around two-thirds of patients with SLE in Europe use hydroxychloroquine to manage their symptoms, and it is the only known therapy so far for primary Sjögren's syndrome, he says.

  • 原文来源：https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(20)30089-8/fulltext
98浏览量
原文链接
相关报告

  • 《LANCET，3月4日，Liver injury in COVID-19: management and challenges》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-03-05
    • Liver injury in COVID-19: management and challenges Chao Zhang, Lei Shi, Fu-Sheng Wang Published:March 04, 2020DOI:https://doi.org/10.1016/S2468-1253(20)30057-1 In December, 2019, an outbreak of a novel coronavirus (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], previously 2019-nCoV) started in Wuhan, China, and has since become a global threat to human health. The number of confirmed cases of 2019 coronavirus disease (COVID-19) has reached 87?137 worldwide as of March 1, 2020, according to WHO COVID-19 situation report 41; most of these patients are in Wuhan, China. Many cases of COVID-19 are acute and resolve quickly, but the disease can also be fatal, with a mortality rate of around 3%. Onset of severe disease can result in death due to massive alveolar damage and progressive respiratory failure.
    133浏览量
    原文链接

  • 《Nature，4月8日，Potential of chloroquine and hydroxychloroquine to treat COVID-19 causes fears of shortages among people with systemic lupus erythematosus》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-04-09
    • Potential of chloroquine and hydroxychloroquine to treat COVID-19 causes fears of shortages among people with systemic lupus erythematosus Deepak Jakhar & Ishmeet Kaur Nature Medicine (2020) To the Editor — In March 2020, in the midst of the COVID-19 pandemic1, reports that chloroquine (CQ) can inhibit the growth of severe acute respiratory syndrome coronavirus (SARS-CoV-2)2,3 have brought this molecule into the spotlight. Hydroxychloroquine (HCQS), which is typically used in dermatology clinics for the management of systemic lupus erythematosus (SLE) and has a better clinical safety profile and fewer drug–drug interactions than CQ, has also been demonstrated to have anti-SARS-CoV activity in vitro2,4. Now, amid the speculation regarding the beneficial roles of these molecules in COVID-19 treatment, shortages of CQ and HCQS are feared.
    104浏览量
    原文链接